Aibotics, Inc.

Overview

Aibotics, Inc. (formerly Mycotopia Therapies, Inc.; name change filed February 3, 2025) is a Nevada corporation that operates through its wholly owned Florida subsidiary, Aibotics Therapies Inc. The company promotes the study of psychedelics for mental health treatment, supports development of natural and synthetic molecules for potential therapies, and plans to deploy AI-enabled technology from its parent company, Ehave, Inc., to collect research and clinical data on psychedelic-assisted treatments. Aibotics acquired assets from Philon Labs, including intellectual property related to the Phill Robot and Milky Way products.

Leadership and governance

• Board of Directors: Ben Kaplan and Mark Croskey

Business activities

• Support research and clinical study of psychedelics for mental health conditions such as depression and anxiety.
• Support development of natural and synthetic molecules targeting psychedelic-assisted therapies.
• Deploy AI-enabled tools from parent company Ehave, Inc. to collect research and clinical data.
• Move toward using AI and robotics to convert concepts into products, improve patient care, and streamline medical processes.
• Build distribution channels for naturally derived psilocybin compounds, with goals to meet regulatory standards (for example, EU GMP) and enable movement of active pharmaceutical ingredients (APIs) where permitted.
• Strategic focus over the next five years on palliative care, depression, and anxiety.

Key assets and products

• Phill Robot
  • AI-powered massage robot intended as a compact home wellness device with multiple massage patterns and a foldable long-range arm.
  • Features: 35-inch range, 15-pound massage force; folds to function as a nightstand.
  • Market position: Consumer product; not marketed as a medical device or subject to FDA device regulation.
• Milky Way
  • Smart refrigerator for breast milk storage with a vertical rotating storage system and real-time temperature and inventory updates via a companion app.
  • Capacity options: standard up to 99 bags; custom units for 120+ bags suited for hospitals or lactation rooms.
  • Market position: Consumer product; not marketed as a medical device.
• Research and data initiatives
  • Plans to integrate EEG brain-cap technology via Ehave to capture neurological data during psychedelic-related therapies; negotiations with third parties are in progress.

Corporate history and structure

• Originally incorporated as RM Investors, Inc. (Nevada) on January 21, 2000.
• 2014: Reorganized through acquisition of 20/20 Produce Sales, Inc.; corporate name changed to 20/20 Global, Inc.
• 2020–2021: Acquisitions and restructurings involving Ehave, Aibotics Therapies Inc. (Florida), and MYC; MYC became a wholly owned subsidiary of 20/20 Global.
• 2021: Corporate name changed to Aibotics Therapies Inc.; MYC designated as a subsidiary.
• 2025: Corporate name changed to Aibotics, Inc.
• Subsidiary: Aibotics Therapies Inc. (Florida).

Market context and strategy

• References state-level and market context for psychedelics, including Oregon’s psilocybin legalization.
• Market projections cited in filings: compound annual growth of roughly 12.4% over seven years and potential market sizes in the 2027 timeframe (examples include global and U.S. estimates).
• Strategic aims:
  • Build a pipeline of pharmaceutical-grade components for psychedelic-based treatments.
  • Develop distribution channels for natural psilocybin-derived ingredients for research and potential therapies.
  • Pursue regulatory-compliant pathways to move APIs across jurisdictions where psilocybin is legal.

Regulatory and compliance posture

• Psychedelics and related therapies are subject to federal, state, and foreign regulation under frameworks such as the FDA, CSA, and DEA.
• Aibotics states it is not directly manufacturing, producing, or selling psilocybin; the company intends to support research and development through compliant partners.
• Phill Robot and Milky Way are positioned and marketed as consumer products rather than medical devices.

Intellectual property and transactions

• Asset Purchase Agreement and IP Assignment with Philon Labs dated November 28, 2024, covering certain assets and IP related to Phill Robot and Milky Way.
• Consideration structure included issuance of a new class of Preferred Stock with a face value of $2,000,000 convertible into common stock.
• During the year ended December 31, 2025, the company issued 200,000 shares of Series B Preferred Stock to the seller as consideration for intangible assets.
• Preferred and common stock issued in connection with the transaction are restricted securities under Rule 144.
• Employment-related incentives tied to revenue could result in up to $7,000,000 of Preferred Stock being issued to employees over three years.

Operations and facilities

• No owned physical properties; the company operates virtually and has no leased offices at present.
• The company assesses current facilities as adequate for immediate needs and would seek additional space if expansion is required.

Cybersecurity

• Maintains a multi-layer cybersecurity program that includes:
  • Multi-factor authentication and credential management
  • Restricted physical access to local servers and NAS devices
  • Employee training and anti-phishing measures
  • Routine virus scanning and software updates
  • Data handling policies and third-party email scanning
  • IT installation controls, incident response planning
  • Governance overseen by a designated CISO and board-level oversight

Legal and disclosures

• No material legal proceedings were reported as of the filing.
• Cybersecurity practices and governance are documented in a dedicated section of the filing.